Biomarkers in atrial fibrillation and heart failure with non-reduced ejection fraction: Diagnostic application and new cut-off points |
| |
| Institution: | 1. Cardiology Department, Universitary Hospital of Burgos, Burgos, Spain;2. Clinical Analyses Department, Universitary Hospital of Burgos, Burgos, Spain;3. Laboratory of Medicine, Central Hospital of Asturias, Oviedo, Spain;4. Universidad Isabel I, Burgos, Spain;1. Department of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States;2. Department of Cardiovascular Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States;3. University College Cork School of Medicine, College Road, Cork T12 K8AF, Ireland;1. University of Nebraska Medical Center, United States;2. Division of Pulmonary, Critical Care, Sleep, and Occupational Medicine;3. Marquette University, United States;4. Mayo Clinic, United States;1. VA-Connecticut Healthcare System, West Haven, CT, United States;2. Yale School of Medicine, New Haven, CT, United States;3. Mount Sinai Health System, New York, NY, United States;4. Yale School of Nursing, P.O. Box 27399, West Haven, CT 06516, United States;1. Department of Intensive Care Unit, The Second Hospital of Shandong University, Jinan 250033, China;2. Department of Respiratory Medicine, The Second Hospital of Shandong University, Jinan 250033, China;3. Department of Emergency, The Second Hospital of Shandong University, Jinan 250033, China;4. Department of Infectious Diseases and Hepatology, The Second Hospital of Shandong University, Jinan 250033, China |
| |
| Abstract: | BackgroundAtrial fibrillation (AF) and heart failure (HF) with non-reduced left ventricle ejection fraction (LVEF) present a diagnostic overlap. In this paper, we analyze differences in biomarkers between patients with and without HF, in a cohort of patients presenting with symptomatic AF. Differences in biomarkers between patients with medium range ejection fraction HF (HFmrEF) and those with preserved ejection fraction HF (HFpEF) are also analyzed.MethodsA total of 115 patients with symptomatic persistent AF were included. Seven biomarkers were measured: NT-proBNP, high sensitivity T troponin (hsTNT), galectin-3, ST2, fibrinogen, urate and C-reactive protein.ResultsPatients with non-reduced LVEF HF had significantly higher NT-proBNP levels than those without HF. This biomarker was the only variable independently related with the presence of non-reduced LVEF HF. Troponin was the only factor independently related with the presence of HFmrEF.ConclusionsNT-proBNP showed the best diagnostic accuracy for detecting the presence of non-reduced LVEF HF. We found higher diagnostic NT-proBNP cut-off values than those previously reported. Troponin was the most accurate biomarker differentiating HFmrEF from HFpEF. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
